KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema

▤ Summary

KalVista Pharmaceuticals shared new data showing that injectable on-demand treatment creates a heavy burden for young children with hereditary angioedema and their caregivers. The data point to high anxiety, delayed treatment, off-label use, and substantial emergency care utilization in the 2–11 age group. KalVista says the findings support the need for an easier oral option and highlight EKTERLY as a potential solution. The company also said it continues its pediatric trial and plans to submit a regulatory filing for sebetralstat in children in the third quarter of 2026.

▦ Linked Companies